Implications of the global increase of diabetes for tuberculosis control and patient care

Tropical Medicine and International Health

Volumn 15, Issue 11, 2010, Pages 1289-1299

  Ruslami, Rovina ^a   Aarnoutse, Rob E ^b   Alisjahbana, Bachti ^a,c   Van Der Ven, Andre J A M ^b   Van Crevel, Reinout ^b  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Hasan Sadikin Hospital   (Indonesia)

Author keywords

Diabetes; Epidemiology; Tuberculosis control

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

BODY MASS; DATABASE; DEVELOPING WORLD; DIABETES; DISEASE CONTROL; DISEASE TREATMENT; DRUG; EPIDEMIOLOGY; LITERATURE REVIEW; TUBERCULOSIS;

AGE; ARTICLE; BANGLADESH; BODY WEIGHT; CHINA; CONGO; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG METABOLISM; ETHIOPIA; GLYCEMIC CONTROL; HUMAN; INDIA; INDONESIA; KNOWLEDGE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; NIGERIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAKISTAN; PATIENT CARE; PATIENT COMPLIANCE; PHILIPPINES; RISK FACTOR; SOUTH AFRICA; SPUTUM CULTURE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG INTERACTIONS; EPIDEMICS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS; YOUNG ADULT;

EID: 79251486358     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02625.x     Document Type: Article

References (75)

1. Alisjahbana B, Van Crevel R, Sahiratmadja E et al. (2006) Diabetes mellitus is strongly associated with tuberculosis in Indonesia. The International Journal of Tuberculosis and Lung Disease 10, 696-700.
2. Alisjahbana B, Sahiratmadja E, Nelwan EJ et al. (2007) The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clinical Infectious Diseases 45, 428-435.
3. American Thoracic Society (ATS) & the Centers for Disease Control and Prevention (CDC) (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory Critical Care Medicine 161, s221-s224.
4. Bacakoglu F, Basoglu OK, Cok G, Sayiner A & Ates M (2001) Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 68, 595-600.
5. Balde NM, Camara A, Camara LM, Diallo MM, Kake A & Bah-Sow OY (2006) Associated tuberculosis and diabetes in Conakry, Guinea: prevalence and clinical characteristics. The International Journal of Tuberculosis and Lung Disease 10, 1036-1040.
6. Banu Rekha VV, Balasubramanian R, Swaminathan S et al. (2007) Sputum conversion at the end of intensive phase of category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: an analysis of risk factors. Indian Journal of Medical Research 126, 452-458.
7. Banyai AL (1959) Diabetes and tuberculosis. Chest 36, 238-242.
8. Bashar M, Alcabes P, Rom WN & Condos R (2001) Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 120, 1514-1549.
9. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS & Brosen K (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. European Journal of Clinical Pharmacology 60, 109-114.
10. Blumberg HM, Burman WJ, Chaisson RE et al. (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 167, 603-662.
11. Boucot KR, Dillon ES, Cooper DA, Meier P & Richardson R (1952) Tuberculosis among diabetics: the Philadelphia survey. American Review of Tuberculosis 65, 1-50.
12. Burman WJ, Gallicano K & Peloquin C (2001) Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clinical Pharmacokinetics 40, 327-341.
13. Campbell RK, White JR Jr & Saulie BA (1996) Metformin: a new oral biguanide. Clinical Therapeutics 18, 360-371.
14. Coker R, McKee M, Atun R et al. (2006) Risk factors for pulmonary tuberculosis in Russia: case-control study. British Medical Journal 332, 85-87.
15. Dooley KE & Chaisson R (2009) Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infectious Diseases 9, 737-746.
16. Dooley KE, Tang T, Golub JE, Dorman SE & Cronin W (2009) Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. American Journal of Tropical Medicine and Hygiene 80, 634-639.
17. Duckworth WC, Bennett RG & Hamel FG (1998) Insulin degradation: progress and potential. Endocrine Review 19, 608-624.
18. Feleke Y, Abdulkadir J & Aderaye G (1999) Prevalence and clinical features of tuberculosis in Ethiopian diabetic patients. East African Medical Journal 76, 361-364.
19. Fisher-Hoch SP, Whitney E, McCormick JB et al. (2008) Type 2 diabetes and multidrug-resistance. Scandinavian Journal of Infectious Disease 40, 888-893.
20. Harries AD, Billo N & Kapur A (2009) Links between diabetes mellitus and tuberculosis: should we integrate screening and care? Transaction of the Royal Society of Tropical Medicine and Hygiene 103, 1-2.
21. Harries AD, Murray MB, Jeon CY et al. (2010) Defining the research agenda to reduce the joint burden of disease from Diabetes mellitus and Tuberculosis. Tropical Medicine and International Health 15, 659-663.
22. Hatorp V, Hansen KT & Thomsen MS (2003) Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. Journal of Clinical Pharmacology 43, 649-660.
23. Hendy HH & Stableforth D (1983) The effect of established diabetes mellitus on the presentation of infiltrative pulmonary tuberculosis in the immigrant Asian community of inner city area in United Kingdom. British Journal of Diseases of the Chest 77, 87-90.
24. Ikezoe J, Takeuchi N, Johkoh T et al. (1992) CT appearance of pulmonary tuberculosis in diabetic and immunocompromised patients: comparison with patients who had no underlying disease. American Journal of Roentgenology 159, 1175-1179.
25. Jaakkola T, Backman JT, Neuvonen M, Laitila J & Neuvonen PJ (2006) Effect of rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology 61, 70-78.
26. Jeon CY, Harries AD, Baker MA et al. (2010) Bi-directional screening for tuberculosis and diabetes: a systematic review. Tropical Medicine and International Health 15, 1300-1314.
27. Jeon CY & Murray MB (2008) Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Medicine 5, e152.
28. Kim SJ, Hong YP, Lew WJ, Yang SC & Lee EG (1995) Incidence of pulmonary tuberculosis among diabetics. Tuberculosis and Lung Disease 76, 529-533.
29. Luntz GR (1957) Management of the tuberculosis diabetic; follow-up of 84 cases for one year. British Medical Journal 1, 1082-1086.
30. Marrais RM (1980) Diabetes mellitus in black and colored tuberculosis patients. South African Medical Journal 57, 483-484.
31. Mitchison DA (2000) Role of individual drugs in the chemotherapy of tuberculosis. International Journal of Tuberculosis and Lung Disease 4, 796-806.
32. Morris JT, Seaworth BJ & McAllister CK (1992) Pulmonary tuberculosis in diabetics. Chest 102, 539-541.
33. Mugusi F, Swai AB, Alberti KG & McLarty DG (1990) Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 71, 271-276.
34. Nathan DM, Buse JB, Davidson MD et al. (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 29, 1963-1972.
35. Niemi M, Kivisto KT, Backman JT & Neuvonen PJ (2000a) Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. British Journal of Clinical Pharmacology 50, 591-595.
36. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ & Kivisto KT (2000b) Rifampin decreases the plasma concentrations and effects of repaglinide. Clinical Pharmacology and Therapeutics 68, 495-500.
37. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ & Kivisto KT (2001) Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clinical Pharmacology and Therapeutics 69, 400-406.
38. Niemi M, Backman JT, Fromm MF, Neuvonen PJ & Kivisto KT (2003a) Pharmacokinetic interactions with rifampicin: clinical relevance. Clinical Pharmacokinetics 42, 819-850.
39. Niemi M, Backman JT, Neuvonen M & Neuvonen PJ (2003b) Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. British Journal of Clinical Pharmacology 56, 427-432.
40. Niemi M, Backman JT & Neuvonen PJ (2004) Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics 76, 239-249.
41. Nijland HM, Ruslami R, Stalenhoef JE et al. (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clinical Infectious Diseases 43, 848-854.
42. Nissapatorn V, Kuppusamy I, Jamaiah I, Fong MY, Rohela M & Anuar AK (2005) Tuberculosis in diabetic patients: a clinical perspective. Southeast Asian Journal of Tropical Medicine and Public Health 36(Suppl. 4), 213-220.
43. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS & Chaisson RE (2002) Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clinical Infectious Diseases 34, 752-759.
44. Pablos-Mendez A, Blustein J & Knirsch CA (1997) The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. American Journal of Public Health 87, 574-579.
45. Park JY, Kim KA, Park PW, Park CW & Shin JG (2003) Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clinical Pharmacology and Therapeutics 74, 334-340.
46. Park JY, Kim KA, Kang MH, Kim SL & Shin JG (2004) Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clinical Pharmacology and Therapeutics 75, 157-162.
47. Park-Wyllie LY, Juurlink DN, Kopp A et al. (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. The New England Journal of Medicine 354, 1352-1361.
48. Perez A, Brown HS III & Restrepo BI (2006) Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. American Journal of Tropical Medicine and Hygiene 74, 604-611.
49. Perez-Guzman C, Torres-Cruz A, Villareal-Velarde H & Vargas MH (2000) Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. American Journal of Respiratory and Critical Care Medicine 162, 1738-1780.
50. Perez-Guzman C, Torres-Cruz A, Villareal-Velarde H, Salazar-Lezama MA & Vargas MH (2001) Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. International Journal of Tuberculosis and Lung Disease 5, 455-461.
51. Ponce-de-Leon A, Garcia-Garcia ML, Garcia-Sancho MC et al. (2004) Tuberculosis and diabetes in southern Mexico. Diabetes Care 27, 1584-1590.
52. Restrepo BI, Fisher-Hoch SP, Crespo JG et al. (2007) Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiology and Infection 135, 483-491.
53. Restrepo BI, Fisher-Hoch SP, Smith B, Jeon S, Rahbar MH & McCormick JB (2008a) Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes. American Journal of Tropical Medicine and Hygiene 79, 541-544.
54. Restrepo BI, Fisher-Hoch SP, Pino PA et al. (2008b) Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clinical Infectious Diseases 47, 634-641.
55. Ridzon R, Whitney CG, McKenna MT et al. (1998) Risk factors for rifampin mono-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 157, 1881-1884.
56. Root HF (1934) The Association of Diabetes and Tuberculosis; Epidemiology, Pathology, Treatment and Prognosis. The New England Journal of Medicine 210, 1-13.
57. Ruslami R, Nijland HMJ, Adhiarta IGN et al. (2010) Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrobial Agent and Chemotherapy 54, 1068-1074.
58. Sahai J, Gallicano K, Swick L et al. (1997) Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Annals of Internal Medicine 127, 289-293.
59. Shaikh MA, Singla R, Khan NB, Sharif NS & Saigh MO (2003) Does diabetes alter the radiological presentation of pulmonary tuberculosis? Saudi Medical Journal 24, 278-281.
60. Shetty N, Shemko M, Vaz M & D'Souza G (2006) An epidemiological evaluation of risk factors for tuberculosis in South India: a matched case control study. International Journal of Tuberculosis and Lung Diseases 10, 80-86.
61. Singla R, Khan N, Al-Sharif N, Ai-Sayegh MO, Shaikh MA & Osman MM (2006) Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. International Journal of Tuberculosis and Lung Diseases 10, 74-79.
62. Stalenhoef JE, Alisjahbana B, Nelwan EJ et al. (2008) The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. European Journal of Clinical Microbiology and Infectious Diseases 27, 97-103.
63. Stevenson CR, Forouhi NG, Roglic G et al. (2007) Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234.
64. Subhash HS, Ashwin I, Mukundan U et al. (2003) Drug resistant tuberculosis in diabetes mellitus: a retrospective study from south India. Tropical Doctor 33, 154-156.
65. Swai AB, McLarty DG & Mugusi F (1990) Tuberculosis in diabetic patients in Tanzania. Tropical Doctor 20, 147-150.
66. Syvalahti E, Pihlajamaki K & Iisalo E (1976) Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide. Internal Journal of Clinical Pharmacology and Biopharmacy 13, 83-89.
67. Umut S, Tosun GA & Yildirim N (1994) Radiographic location of pulmonary tuberculosis in diabetic patients. Chest 106, 326.
68. Venkatesan K (1992) Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics 22, 47-65.
69. Al-Wabel AH, Teklu B, Mahfouz AA, Al-Ghamdi AS, El-Amin OB & Khan AS (1997) Symptomatology and chest roentgenographic changes of pulmonary tuberculosis among diabetics. East African Medical Journal 74, 62-64.
70. Wang JY, Lee LN & Hsueh PR (2005) Factors changing the manifestation of pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 9, 777-783.
71. Wang CS, Chen HC, Yang CJ et al. (2009) Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiology and Infections 137, 203-210.
72. Weaver R (1974) Unusual radiographic presentation of pulmonary tuberculosis in diabetic patients. American Review of Respiratory Disease 109, 162-163.
73. Weiner M, Benator D, Peloquin CA et al. (2005) Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clinical Infectious Diseases 41, 1343-1349.
74. World Health Organization (2009) WHO report 2009: Global tuberculosis control-surveillance, planning, financing. .
75. Zilly W, Breimer DD & Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. European Journal of Clinical Pharmacology 9, 219-227.